ESMO HIGHLIGHTS 2024 – MELANOMA ROUNDTABLE DISCUSSION: Neoadjuvant/Adjuvant Therapy
OR
Chapter selection available inside video player. Click here for outline.
01:40
LBA43 Adjuvant nivolumab v placebo in stage IIB/C melanoma: 3-year results from CheckMate 76K
04:57
1078MO Pembrolizumab (pembro) vs placebo as adjuvant therapy for high-risk stage II melanoma: Long-term follow-Up, rechallenge, and crossover in KEYNOTE-716
06:58
1082O KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) and investigational agents followed by adjuvant pembro for stage IIIB-D melanoma
11:29
LBA42 Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: the NADINA trial
19:12
LBA41 Long-term survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
Chair
Dr. Teresa Petrella
Panelists
Dr. Marcus Butler
Dr. Caroline Robert
